References
- American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/ hyperactivity disorder. Pediatrics 2000;105:1158–70
- Rappley MD. Clinical practice. Attention deficit-hyperactivity disorder. New Engl J Med 2005;352:165–73
- Diagnostic and statistical manual of mental disorders, 4th ed. [revised (DSM-IV-R)]. Washington (DC): American Psychiatric Association; 2000
- Robison LM, Sclar DA, Skaer TL, Galin RS. National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990–1995. Clin Pediatr (Phila) 1999;38:209–17
- Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents [Council on Scientific Affairs, American Medical Association]. J Am Med Assoc 1998;279:1100–7
- American Academy of Pediatrics. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 2001;108:1033–44
- Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991;148:564–77
- Ray GT, Levine P, Croen LA, et al. Attention-deficit/hyperactivity disorder in children: excess costs before and after initial diagnosis and treatment cost differences by ethnicity. Arch Pediatr Adolesc Med 2006;160:1063–9
- Birnbaum HG, Kessler RC, Lowe SW, et al. Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin 2005;21:195–206
- Jensen PS, Hinshaw SP, Swanson JM, et al. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. J Dev Behav Pediatr 2001;22:60–73
- MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics 2004;113:754–61
- Zito JM, Safer DJ, dosReis S, et al. Psychotherapeutic medication patterns for youths with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 1999;153:1257–63
- LeFever GB, Dawson KV, Morrow AL. The extent of drug therapy for attention deficit-hyperactivity disorder among children in public schools. Am J Public Health 1999;89:1359–64
- Abikoff H, Hechtman L, Klein RG, et al. Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry 2004;43:802–11
- Green W. The treatment of attention deficit hyperactivity disorder with nonstimulant medications. Child Adolesc Psychiatr Clin North Am 1995;4:169–95
- Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996;35:409–32
- Greenhill L. Attention deficit hyperactivity disorder: the stimulants. Child Adolesc Psychiatr Clin North Am 1995;4:123–68
- Kent JD, Blader JC, Koplewicz HS, et al. Effects of late-afternoon methylphenidate administration on behavior and sleep in attention-deficit hyperactivity disorder. Pediatrics 1995;96:320–5
- Cohen-Zion M, Ancoli-Israel S. Sleep in children with attention-deficit hyperactivity disorder (ADHD): a review of naturalistic and stimulant intervention studies. Sleep Med Rev 2004;8:379–402
- O’Brien LM, Ivanenko A, Crabtree VM, et al. The effect of stimulants on sleep characteristics in children with attention deficit/hyperactivity disorder. Sleep Med 2003;4:309–16
- Day HD, Abmayr SB. Parent reports of sleep disturbances in stimulant-medicated children with attention-deficit hyperactivity disorder. J Clin Psychol 1998;54:701–16
- Corkum P, Moldofsky H, Hogg-Johnson S, et al. Sleep problems in children with attention-deficit/hyperactivity disorder: impact of subtype, comorbidity, and stimulant medication. J Am Acad Child Adolesc Psychiatry 1999;38:1285–93
- Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/ hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics [serial online] 2004;114:e1–e8
- Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose– response study. Pediatrics [serial online] 2001;108:e83
- Michelson D, Buitelaar JK, Danckaerts M, et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 2004;43:896–904
- Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003;53:112–20
- Black N. Why we need observational studies to evaluate the effectiveness of health care. Br Med J 1996;312:1215–8
- Wolraich ML. The difference between efficacy and effectiveness research in studying attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 1999;153:1220–1
- Döpfner M, Breuer D, Schürman S, et al. Effectiveness of an adaptive multimodal treatment in children with attention-deficit hyperactivity disorder: global outcome. Eur Child Adolesc Psychiatry 2004;15(Suppl 1):i117–i129
- Rothenberger A, Coghill D, Döpfner M, et al. Naturalistic-observational studies in the framework of ADHD health care. Eur Child Adolesc Psychiatry 2006;15(Suppl 1):i1–i13
- Ralston SJ, Lorenzo MJM, the ADORE Study Group. ADORE – attention-deficit hyperactivity disorder observational research in Europe. Eur Child Adolesc Psychiatry 2004;13(Suppl 1):i36–i42
- Eli Lilly: Strattera® (atomoxetine HCl) US full prescribing information. Available at http://pi.lilly com/us/strattera-pi.pdf [accessed October 6, 2006]
- Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002;63:1140–7
- Guevara JP, Stein MT. Evidence based management of attention deficit hyperactivity disorder. Br Med J 2001;323:1232–5
- Bangs ME, Emslie GJ, Spencer TJ, et al.; for the Atomoxetine ADHD and Comorbid MDD Study Group (LYAX). Efficacy and safety of atomoxetine treatment in adolescents with ADHD and major depressive disorder. J Child Adolesc Psychopharmacol 2007 [in press]
- Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 2005;65:1941–9
- Steinhausen H-C, Stene Nǿvik T, Baldusrsson G, et al.; the ADORE Study Group. Co-existing problems in ADHD in the ADORE cohort. Eur Child Adolesc Psychiatry 2006;15 (Suppl 1):i25–i29
- Olfson M, Gameroff MJ, Marcus SC, Jensen PS. National trends in the treatment of attention deficit hyperactivity disorder. Am J Psychiatry 2003;160:1071–7
- Loeber R, Green SM, Lahey BB, Stouthamer-Loeber M. Differences and similarities between children, mothers, and teachers as informants on disruptive child behavior. J Abnorm Child Psychol 1991;19:75–95
- Mitsis EM, McKay KE, Schulz KP, et al. Parent–teacher concordance for DSM-IV attention-deficit/hyperactivity disorder in a clinic-referred sample. J Am Acad Child Adolesc Psychiatry 2000;39:308–13